Yin Jiajia, Wang Chenxi, Zhao Lei, Xu Kang, Guo Yuxin, Song Xuejiao, Shao Jinjun, Xu Huae, Dong Xiaochen
Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), School of Physical and Mathematical Sciences, Nanjing Tech University (NanjingTech), Nanjing, 211816, China.
School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou, 221116, China.
Biomaterials. 2023 May;296:122094. doi: 10.1016/j.biomaterials.2023.122094. Epub 2023 Mar 15.
Since the hypoxia tumor microenvironment (TME) will not only limit the treatment effect but also cause tumor recurrence and metastasis, intratumoral aggravated hypoxia level induced by vascular embolization is one of the major challenges in tumor therapy. The chemotherapeutic effect of hypoxia-activated prodrugs (HAPs) could be enhanced by the intensified hypoxia, the combination of tumor embolization and HAP-based chemotherapy exhibits a promising strategy for cancer therapy. Herein, an acidity-responsive nanoplatform (TACC NP) with multiple pathways to benefit the hypoxia-activated chemotherapy is constructed by loading the photosensitizer Chlorin e6 (Ce6), thrombin (Thr), and AQ4N within the calcium phosphate nanocarrier via a simple one-pot method. In the acidic TME, TACC NPs could be degraded to release Thr and Ce6, resulting in the destruction of tumor vessels and consumption of intratumoral oxygen under laser irradiation. Therefore, the intratumoral hypoxia level could be significantly aggravated, further leading to the enhanced chemotherapeutic effect of AQ4N. With the guidance of in vivo fluorescence imaging, the TACC NPs exhibited excellent tumor embolization/photodynamic/prodrug synergistic therapeutic effects with good biosafety.
由于缺氧肿瘤微环境(TME)不仅会限制治疗效果,还会导致肿瘤复发和转移,血管栓塞诱导的瘤内缺氧水平加剧是肿瘤治疗中的主要挑战之一。缺氧激活前药(HAPs)的化疗效果可通过强化缺氧来增强,肿瘤栓塞与基于HAP的化疗相结合展现出一种很有前景的癌症治疗策略。在此,通过一种简单的一锅法将光敏剂二氢卟吩e6(Ce6)、凝血酶(Thr)和AQ4N负载于磷酸钙纳米载体中,构建了一种具有多种途径有利于缺氧激活化疗的酸度响应纳米平台(TACC NP)。在酸性TME中,TACC NPs可降解以释放Thr和Ce6,从而在激光照射下导致肿瘤血管破坏和瘤内氧气消耗。因此,瘤内缺氧水平可显著加剧,进而导致AQ4N的化疗效果增强。在体内荧光成像的引导下,TACC NPs展现出优异的肿瘤栓塞/光动力/前药协同治疗效果以及良好的生物安全性。